Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 864

The DOI matches its Crossref record; 442 of the 442 references it cites were found in a registry or an index.

Broad targeting of resistance to apoptosis in cancer

Open access
Mohammad, Ramzi M., Muqbil, Irfana, Lowe, Leroy, Yedjou, Clement, Hsu, Hsue-Yin, Lin, Liang-Tzung, Siegelin, Markus David, Fimognari, Carmela, Kumar, Nagi B., Dou, Q. Ping, Yang, Huanjie, Samadi, Abbas K., Russo, Gian Luigi, Spagnuolo, Carmela, Ray, Swapan K., Chakrabarti, Mrinmay, Morre, James D., Coley, Helen M., Honoki, Kanya, Fujii, Hiromasa, Georgakilas, Alexandros G., Amedei, Amedeo, Niccolai, Elena, Amin, Amr, Ashraf, S. Salman, Helferich, William G., Yang, Xujuan, Boosani, Chandra S., Guha, Gunjan, Bhakta, Dipita, Ciriolo, Maria Rosa, Aquilano, Katia, Chen, Sophie, Mohammed, Sulma I., Keith, W. Nicol, Bilsland, Alan, Halicka, Dorota, Nowsheen, Somaira, Azmi, Asfar S. · 2015 · Seminars in Cancer Biology

Abstract

Apoptosis or programmed cell death is natural way of removing aged cells from the body. Most of the anti-cancer therapies trigger apoptosis induction and related cell death networks to eliminate malignant cells. However, in cancer, de-regulated apoptotic signaling, particularly the activation of an anti-apoptotic systems, allows cancer cells to escape this program leading to uncontrolled proliferation resulting in tumor survival, therapeutic resistance and recurrence of cancer. This resistance is a complicated phenomenon that emanates from the interactions of various molecules and signaling pathways. In this comprehensive review we discuss the various factors contributing to apoptosis resistance in cancers. The key resistance targets that are discussed include (1) Bcl-2 and Mcl-1 proteins; (2) autophagy processes; (3) necrosis and necroptosis; (4) heat shock protein signaling; (5) the proteasome pathway; (6) epigenetic mechanisms; and (7) aberrant nuclear export signaling. The shortcomings of current therapeutic modalities are highlighted and a broad spectrum strategy using approaches including (a) gossypol; (b) epigallocatechin-3-gallate; (c) UMI-77 (d) triptolide and (e) selinexor that can be used to overcome cell death resistance is presented. This review provides a roadmap for the design of successful anti-cancer strategies that overcome resistance to apoptosis for better therapeutic outcome in patients with cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2015.03.001

Cites

442 of 442 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Items 201–400 of 442

Cited by

See all 864

Metadata

Authors
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., Yang, H., Samadi, A. K., Russo, G. L., Spagnuolo, C., Ray, S. K., Chakrabarti, M., Morre, J. D., Coley, H. M., Honoki, K., Fujii, H., Georgakilas, A. G., Amedei, A., Niccolai, E., Amin, A., Ashraf, S. S., Helferich, W. G., Yang, X., Boosani, C. S., Guha, G., Bhakta, D., Ciriolo, M. R., Aquilano, K., Chen, S., Mohammed, S. I., Keith, W. N., Bilsland, A., Halicka, D., Nowsheen, S., & Azmi, A. S.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2015-12
Volume
35
Pages
S78-S103
ISSN
1044-579X (ISSN-L)
OpenAlex
W2072860434
Cited by
864
References
442
FWCI
17.50
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.